Search Results

Connect Biopharma Holdings Limited announced that two of its wholly owned subsidiaries, Connect Biopharma Hong Kong Limited and Suzhou Connect Biopharma Co., Ltd., have entered into an exclusive license and collaboration agreement with Simcere Pharmaceutical Co., Ltd., a subsidiary of Simcere Pharmaceutical Group Ltd., to develop and commercialize Connect Biopharma’s rademikibart in Greater China.

Connect Biopharma Holdings Limited announced today that Barry Quart, Chief Executive Officer, David Szekeres, President and Steven Chan, Chief Financial officer will be hosting one-on-one investor meetings at the Leerink Partners Inflammation and Immunology (I&I) and Metabolism Therapeutics Forum, taking place on July 9-10, 2024 in Boston, MA.

Gritgen Therapeutics Co., Ltd., a biotechnology company focused on discovering and developing innovative gene therapy products, announces the successful validation and official launching of operations at its commercial GMP facility located in Suzhou Industrial Park.

NeoMab Biotechnology Co., Ltd. celebrated its grand opening in Suzhou Industrial Park.

Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma,” “Connect” or the “Company”) today reported financial results for the year ended December 31, 2023, and provided a business update.

Suzhou GenAssist Therapeutic Co.,Ltd recently announced its pre-IND application of their first base editing product, GEN6050 and the acceptance by the FDA.

Connect Biopharma Holdings Limited announced the appointments of Barry Quart, Pharm.D., as Chief Executive Officer and Director, David Szekeres as President, and Kleanthis G. Xanthopoulos, Ph.D., as the new Chair of the Board of Directors.

Autobahn Therapeutics today announced that Kevin Finney, President and Chief Executive Officer, will participate in the Leerink Partners Biopharma Private Company Connect on Wednesday, June 26, 2024.